National Health Investors Inc. (NHI) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
National Health Investors’s revenue went from $248M in fiscal 2016 to $376M in fiscal 2025, growth of about 4.7% a year.
Net income in fiscal 2025 was $142M, a net margin of 37.9%; the best year in this period was 2020 with $185M.
Over the twelve months to September 30, 2026, revenue was $456M and net income $697M.
Free cash flow was -$57M in fiscal 2025 and positive in 8 of the 10 years shown.
The diluted share count rose 20% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $456M | $376M | $335M | $320M | $278M | $299M | $333M | $318M | $295M | $279M | $248M |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — | — |
| Net income | $697M | $142M | $138M | $136M | $66M | $112M | $185M | $160M | $154M | $159M | $152M |
| EPS (diluted) | $14.24 | $3.02 | $3.13 | $3.13 | $1.48 | $2.44 | $4.14 | $3.67 | $3.67 | $3.87 | $3.87 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +12.1% | +4.8% | +15.0% | −6.9% | −10.2% | +4.6% | +8.0% | +5.7% | +12.2% | +8.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $234M | $237M | $208M | $184M | $185M | $211M | $232M | $241M | $208M | $198M | $177M |
| Capital spending | — | -$294M | -$158M | -$50M | -$11M | -$50M | -$117M | -$237M | -$148M | -$176M | -$395M |
| Free cash flow | $234M | -$57M | $50M | $135M | $174M | $161M | $115M | $4M | $60M | $22M | -$218M |
| Dividends paid | $178M | $170M | $157M | $156M | $162M | $183M | $195M | $180M | $165M | $153M | $138M |
| Buybacks | — | — | $0 | $0 | $152M | $0 | $0 | — | — | — | — |
| Stock-based pay | $7M | $6M | $4M | $5M | $9M | $8M | $3M | $4M | $2M | $3M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $20M | $24M | $22M | $19M | $37M | $43M | $5M | $5M | $3M | $5M |
| Debt | — | $1.2B | $1.1B | $1.1B | $1.1B | $1.2B | $1.5B | $1.4B | $1.3B | $1.1B | $1.1B |
| Equity | — | $1.5B | $1.4B | $1.3B | $1.3B | $1.5B | $1.5B | $1.5B | $1.4B | $1.3B | $1.2B |
| Total assets | — | $2.8B | $2.6B | $2.5B | $2.5B | $2.8B | $3.1B | $3.0B | $2.8B | $2.5B | $2.4B |
| Shares (diluted) | 49M | 47M | 44M | 43M | 45M | 46M | 45M | 44M | 42M | 41M | 39M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — |
| Net margin | 153.0% | 37.9% | 41.2% | 42.4% | 23.9% | 37.4% | 55.6% | 50.4% | 52.4% | 57.2% | 61.0% |
| FCF margin | 51.4% | -15.3% | 14.9% | 42.2% | 62.7% | 53.7% | 34.7% | 1.2% | 20.4% | 8.0% | -87.8% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROE | — | 9.3% | 10.1% | 10.8% | 5.2% | 7.4% | 12.2% | 10.7% | 11.1% | 12.0% | 12.5% |
Frequently asked questions
What is National Health Investors’s annual revenue?
$376M in fiscal 2025 and $456M over the twelve months to September 30, 2026.
How much profit does National Health Investors make?
Net income was $142M in fiscal 2025 (net margin 37.9%).
Is National Health Investors’s revenue growing?
Yes: revenue rose 12.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.